OR WAIT null SECS
August 20, 2021
The user fees set for fiscal year 2022 are noteworthy, as their announcement comes as FDA and industry are finalizing agreements for new five-year user fee programs.
FDA granted orphan drug designation to Paratek Pharmaceuticals for NUZYRA (omadacycline), an investigational antibiotic.
Bristol Myers Squibb has exercised the option to in-license an immune-modulating drug candidate developed by Exscientia.
3P Innovation has won a Princess Royal Training Award for its Graduate Development Programme (GDP).
UK's ABPI responds to the latest revisions being made to NICE methods for assessment of drugs and devices.
August 19, 2021
Curia plans to expand the site’s commercial capabilities with this move.
Merck KGaA has partnered with Telix Pharmaceuticals to conduct combination clinical studies for cancer therapy.
Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.
The collaboration will focus on the interactions between WTX-124 indukine and KEYTRUDA (pembrolizumab).
A new method developed by the NIH bypasses genetic RNA extraction, simplifying the testing process.